The QualityStocks Daily Monday, December 28th, 2020

Today's Top 3 Investment Newsletters

InvestorsUnderground(COUV) +288.21%

QualityStocks(ASTI) +171.43%

Tip.us(INVT) +143.98%

The QualityStocks Daily Stock List

ADVANZ PHARMA Corp. Limited (CXRXF)

Stock Analysis, MarketWatch, Street Insider, BioSpace, MarketBeat, Seeking Alpha, Webull, TeleTrader, The Globe and Mail, GuruFocus, YCharts, Investcom.com, docoh, Investing.com, TradingView, CEO.ca, Dividend Investor, Stockwatch, Stockopedia, FX Empire, OTC Markets, PR Newswire, Wallet Investor, Market Screener, InvestorsHub, Simply Wall St, Fintel, Morningstar, Stockhouse, Barchart, TMX.com, Nasdaq, Newswire.ca, and Dividend.com reported previously on ADVANZ PHARMA Corp. Limited (CXRXF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

ADVANZ PHARMA Corp. Limited is an international pharmaceutical company listed on the OTC Markets. It focuses on serving the needs of patients and healthcare providers globally with enhanced access to high quality, niche-established medicines. It has deep expertise in the Anti-Infectives and Endocrinology therapy areas, along with strong relationships with hospital decision makers. The Company formerly went by the name Concordia International Corp. It changed its name to ADVANZ PHARMA Corp. in November of 2018. ADVANZ PHARMA is headquartered in London, the United Kingdom (UK).

ADVANZ PHARMA operates worldwide from its headquarters in London, England and through its subsidiaries in Dublin, Ireland; Sydney, Australia; Helsingborg, Sweden; Chicago, Illinois; Geneva, Switzerland; and Mumbai, India. The Company has a diverse portfolio of more than 200 branded and unbranded products. Furthermore, it has sales in over 90 countries.

ADVANZ PHARMA is focused on becoming the leading platform for niche-established medicines, with advanced commercial capabilities throughout Western Europe. It is the first Pharma Company in the world to achieve an ISO 37001 accreditation for its comprehensive compliance management system.

ADVANZ PHARMA enables patients and healthcare providers to access high-quality, niche, established medicines through revitalizing and innovating niche, established medicines that without its focus, may otherwise not be available to patients. The Company is investing substantially in its portfolio through a combination of pipeline development and acquisition. It is centered on growing its portfolio to provide more choice for payors, prescribers, and patients and a strong supply so that patients can continue to benefit from these medicines.

In November, ADVANZ PHARMA announced its financial and operational results for the three and nine months ended September 30, 2020.

Mr. Graeme Duncan, Chief Executive Officer of ADVANZ PHARMA, said, “The Company delivered strong financial results during its third quarter and first nine months of 2020. These results demonstrate the important nature of our established portfolio of medicines, and reflect a significant contribution from our recently acquired Alprostadil products, and Correvio Pharma, which we acquired late in our second quarter…”

The Company reported Q3 2020 revenue of $128.7 million, versus $119.6 million for Q3 of 2019, and $131.9 million for Q2 of 2020. It reported a Net Loss for Q3 of 2020 of $42.0 million.

ADVANZ PHARMA Corp. Limited (CXRXF), closed Monday’s trading session at $4.855, off by 2.90%, on 730 volume. The average volume for the last 3 months is 14,501 and the stock's 52-week low/high is $2.13000011/$19.1399993.

Benchmark Metals, Inc. (BNCHF)

Mines and Money, GreenShoeMedia, Newsfilecorp, Streetwise Reports, Investcom.com, Stock Day Media, StocksCafe, Mining Capital, Resource World, Simply Wall St, MarketWatch, IRW Press, Morningstar, Stockhouse, TradingView, Junior Mining Network, Proactive Investors, Dividend.com, Barchart, Nasdaq, Seeking Alpha, Market Screener, TMXmoney, GuruFocus, OTC Markets, and FX Empire reported previously on Benchmark Metals, Inc. (BNCHF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Benchmark Metals, Inc. focuses on proving and developing the major resource potential of the Lawyer's Gold-Silver Project, situated in the prolific Golden Horseshoe of northern British Columbia. The Company is part of the Metals Group portfolio of companies. It formerly went by the name Crystal Exploration, Inc. It changed its corporate name to Benchmark Metals, Inc. in May of 2018. Incorporated in 2010, Benchmark Metals is headquartered in Edmonton, Alberta. The Company lists on the OTC Markets Group’s OTCQX.

Benchmark Metals’ Lawyers Property encompasses 140 km2 of highly prospective rocks in the northeastern area of the prolific metal-endowed Stikine Terrane, British Columbia. The Lawyers Project spans an important stratigraphic horizon between rocks of the Upper Triassic Stuhini Group and Lower Jurassic Hazelton Group that define an important geological unconformity with many of the deposits in the Golden Horseshoe concentrated along it.

This project is also positioned in a proven and profitable mining jurisdiction, only 45 km northwest of the Kemess gold-copper mine. At the core of the Laywers Trend is the structurally controlled Cliff Creek, Dukes Ridge, Phoenix, and AGB zones located within a large 5 km by 8 km radiometric anomaly, which is coincident with potassic alteration, associated with a low-sulphidation epithermal system.

Recently, Benchmark Metals announced that its systematic exploration and drill targeting are continuing to add new areas to its project pipeline with discoveries of major new mineralization at surface and at depth, which may develop into future satellite deposits peripheral to the Cliff Creek, Dukes Ridge, and AGB resource targets. Rock samples collected across new target areas have yielded high-grade results up to 25.90 grams per tonne (g/t) gold and 2,610 g/t silver.

Earlier in December, Benchmark Metals announced the deepest gold-silver mineralization intersected to date at the northern portion of the Cliff Creek deposit. Hole 20CCDD070 intersected significant mineralization at over 425m below surface that extends the depth of the deposit by 50-plue meters below the base of the open pit model and remains open. Further assay results are pending from a tier of holes that extend up to 100m beneath this hole, with the drill core showing similar alteration and visible gold-silver mineralization. The Company stated that the combined results have excellent potential to positively impact the future resource estimate and extent of the open pit model economics.

Benchmark Metals, Inc. (BNCHF), closed Monday’s trading session at $0.88069, off by 0.95704%, on 20,068 volume. The stock's 52-week low/high is $0.119999997/$1.21941995.

BioLife Sciences, Inc. (BLFE)

MicroCapDaily, Emerging Growth, StockInvest.us, Morningstar, BioSpace, MarketBeat, Stock Day Media, Fintel, Dividend Investor, Stocktwits, Market Screener, Corporate Information, Financhill, Stockwatch, YCharts, MarketWatch, GlobeNewswire, NewMediaWire, Stockhouse, Seeking Alpha, OTC Markets, FX Empire, Stockopedia, InvestorsHub, Dividend.com, TipRanks, Barchart, Business Insider, Wallmine, and Simply Wall St reported earlier on BioLife Sciences, Inc. (BLFE), and today we report on the Company, here at the QualityStocks Daily Newsletter.

BioLife Sciences, Inc. specializes in moving innovative products from the laboratory or small-scale production into wider market adoption. The Company’s core business develops, licenses, and distributes antimicrobial products, non-contact human temperature screening technology, as well as touchless vending/marketplaces. In essence, BioLife Sciences is a commercialization accelerator, licensor, and developer of unique and disruptive technologies for the healthcare, beauty and food, and beverage industry sectors. BioLife Sciences is based in Mississauga, Ontario. The Company lists on the OTC Markets.

BioLife Sciences offers a variety of health products, PPE (Personal Protective Equipment), and natural remedies for the consumer market. The Company offers inventive iterations of everyday products enhanced and complemented by unique scientific breakthroughs. One of its primary building block strategies is to develop, partner, and assist innovative companies with commercialization of leading-edge technologies.

BioLife Sciences’ technology includes Antimicrobial Copper Air Filters; Eco-Safe Surface Sanitizer; Eco-Safe Antimicrobial Treatment; and Copper Infused Textiles. In addition, its technology includes FebriDX POC10-Minute COVID-19 Test; Ultraviolet Sterilization; Non-Contact Human Temperature Screening; and Next- Generation Vending Machines.

BioLife Sciences has its new antimicrobial air filter technology. BioLife Antimicrobial Air Filters provide consumers with the ability to help sanitize the air in their homes or workspaces. This is while providing continuous, long-lasting protection for months. The fabric-based BioLife Antimicrobial Copper Air Filter uses the Company’s proprietary Mfusion Technology. Mfusion Technology infuses copper metal ions into every sub-bundle of the fabric filter. This results in natural protection against bacteria and germs that normally thrive when circulating in an enclosed room, or building.

BioLife Sciences announced this past October the availability of the FebriDx®. This is an ultra-rapid, disposable, point-of-care test device that identifies a clinically significant Acute Respiratory Infection (ARI) and differentiates viral from bacterial causes. The test itself takes only 30 seconds. It provides non-invasive test results for ARIs within 10 minutes. The test is approved by Health Canada for SARS-CoV-2 (COVID-19) virus testing and other viral and bacterial infections.

In November, BioLife Sciences announced it reached an agreement with BeMotion, Inc. for strategic investment to speed up the commercialization of its advanced smart digital vending platform. BeMotion will invest $4.5M USD as a combination of services and capital equipment into BioLife Sciences to fulfill and expand their present contracts. The investment represents a major step towards BioLife Sciences and BeMotion realizing a shared vision of smart digital vending that provides a solution to last-mile product distribution in the rapidly shifting landscape of retail that is re-shaping where and how consumers buy products.

BioLife Sciences, Inc. (BLFE), closed Monday’s trading session at $0.81, off by 2.994%, on 51,051 volume. The average volume for the last 3 months is 42,900 and the stock's 52-week low/high is $0.037/$4.32999992.

CYduct Diagnostics, Inc. (SNDYD)

OTC Markets, Nasdaq, Stock Investor, BioSpace, TipRanks, Trade Ideas, GuruFocus, Market Screener, InvestorsHub, Morningstar, TradingView, Seeking Alpha, Financhill, EOD Data, Business Insider, Macroaxis, MarketWatch, Barchart, Fintel, Simply Wall St, Investors Hangout, Dividend Investor, Tiingo, Baystreet.ca, and Stockhouse reported earlier on CYduct Diagnostics, Inc. (SNDYD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

CYduct Diagnostics, Inc. is a healthcare instrument company established in 1986 and based in Westport, Connecticut. Its mission is to develop and market high quality and unique products for the screening, diagnosis, treatment, and also management of medical conditions. The Company was previously known as Solos Endoscopy, Inc. It changed its name to CYduct Diagnostics, Inc. this. CYduct Diagnostics lists on the OTC Markets.

The Company develops and markets pioneering technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment, and management of disease via minimally invasive methods. CYduct’s products include Laparoscopic Instruments, MammoView™, Endoscopes, Endocouplers, as well as Trocars & Cannulas.

The Company has its aforementioned MammoView™ Breast Endoscopy System. It retrieves cell samples from the lining of the mammary duct. This System employs advanced microendoscopes and optical technology to give physicians sharp, clear images of the milk ducts, where the majority of the breast cancers arise.

Earlier this month, CYduct Diagnostics announced it signed a Letter of Intent (LOI) to acquire all the assets of HHC Preferred LLC. (HHC). CYduct confirmed that it is in advanced talks to buy the assets of HHC. This includes its HALO Nipple Aspirate Fluid (NAF) acquisition system.

The HALO technology is incorporated in a non-invasive device, which employs patented technology to enable physicians to obtain samples of NAF in a clinical setting. These samples can then be used to screen for early identification of breast health risk.

Dom L, Gatto, Chief Executive Officer of CYduct Diagnostics, said, "Upon closing, expected before year-end, the acquisition of the HHC assets are predicted to add appreciably to CYduct Diagnostics' development of innovative approaches and improvements in the breast health market. We believe this action is one more step in a series of initiatives aimed at establishing CYduct Diagnostics' position within this dynamic market."

CYduct Diagnostics, Inc. (SNDYD), closed Monday’s trading session at $0.555, off by 50.4464%, on 164 volume. The stock's 52-week low/high is $0.375/$2.25.

Izotropic Corporation (IZOZF)

TipRanks, WallStreetNation, Healthcare Global, OTC Dynamics, Simply Wall St, Stockopedia, TheNewswire, OTC Markets, Nasdaq, Stockwatch, Stockhouse, Market Screener, Barchart, IRW Press, Dividend.com, Mining Stock Education, Wallet Investor, Market Wire News, TradingView, Newsbreak, Financial Buzz, Macroaxis, Morningstar, CEO.ca, InvestorsHub, Investing News, Investor Intel, The Globe and Mail, MarketWatch, GuruFocus, Newsfilecorp, Seeking Alpha, and Dividend Investor reported beforehand on Izotropic Corporation (IZOZF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Izotropic Corporation and its wholly-owned U.S. operating subsidiary, Izotropic Imaging Corp. were formed to commercialize the next generation of breast imaging technology for early diagnosis of breast cancer. It has the exclusive international license from the University of California, Davis to commercialize the technology developed by principal Founder and Company Director Dr. John M. Boone and researchers at UC Davis. Incorporated in 2016, Izotropic is based in Surrey, British Columbia. The Company lists on the OTC Markets.

Approximately $20 million in research funding and greater than 15 years of research and development (R&D) have been invested in developing this innovative breast CT imaging technology. Research includes a current, continuing $2.9M U.S. clinical trial at UC Davis Medical Center. The aforementioned license includes all intellectual property (IP), trade secrets, patents, and patent-pending applications that are the basis of the Izotropic 's breast CT imaging platform.

The Izotropic Breast CT Imaging System produces high resolution breast images in 3D. A single 10 second breast CT scan acquires roughly 500 images. This is without painful breast compression. This provides radiologists with fully 3D viewing of the scanned breast.

This month, Izotropic announced it received the finalized meeting minutes from the U.S. Food and Drug Administration (FDA) in connection with the Company's recent pre-submission meeting and the market approval process for its commercial Breast CT Imaging System.

Dr. John McGraw, Executive Vice-President of Commercial Operations, stated, "I am pleased to report that the meeting with the FDA was very beneficial for Izotropic and the comments received have validated our clinical study plan and development efforts to date. The initial indication for use for breast CT as a diagnostic device has been confirmed, and we have come away from the meeting with a high degree of confidence in our U.S. market approval plan moving forward."

Izotropic Corporation (IZOZF), closed Monday’s trading session at $1.02, even for the day, on 8,500 volume. The average volume for the last 3 months is 16,945 and the stock's 52-week low/high is $0.081430003/$1.12179994.

PetVivo Holdings, Inc. (PETV)

EIN News, MarketBeat, Nasdaq, OTC Markets, The Globe and Mail, Stock News Now, Stock Analysis, Stockhouse, OTC Dynamics, Equities.com, Investing.com, Fintel, Stock Day Media, BioSpace, CSI Market, Seeking Alpha, Stockopedia, Research and Markets, Morningstar, Business Insider, Make Penny Stocks Great Again, GlobeNewswire, InvestorsHub, Wallet Investor, Market Screener, New to the Street, Dividend Investor, Super Stock Screener, Street Insider, Green Leaf Pot Stocks, Wall Street Alerts, YCharts, Webull, Proactive Investors, Emerging Growth, GuruFocus, and MarketWatch reported beforehand on PetVivo Holdings, Inc. (PETV), and today we report on the Company, here at the QualityStocks Daily Newsletter.

PetVivo Holdings, Inc. is an emerging biomedical device business. Its focus is on the commercialization of innovative medical therapeutics for pets. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient manner. It has a pipeline of 17 products for the treatment of animals and people. PetVivo Holdings is based in Minneapolis, Minnesota. The Company lists on the OTC Markets Group’s OTCQB.

PetVivo also has a portfolio of 18 patents that protects its biomaterials, products, production processes, and methods of use. Its lead product is Kush. This is a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses.

An important part of PetVivo’s strategy to leverage human therapies for the treatment of companion animals in a capital and time efficient manner is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

In 2017, PetVivo Holdings, Inc. completed a merger with Gel-Del Technologies, Inc., which is now a wholly-owned subsidiary of the Company. At first, PetVivo is commercializing its technology in the animal healthcare marketplace for the treatment of osteoarthritis. Nonetheless, it anticipates launching other veterinary and human products in the near-term.

PetVivo Holdings announced this past October the certification and opening of its new medical device manufacturing facility and Center of Excellence in Edina, Minnesota. This new manufacturing facility is chiefly dedicated to the manufacture of its veterinary medical device for the treatment of osteoarthritis (OA), KUSH™, in the $4.8 billion dog and horse therapeutics market, and also the development of its proprietary mucoadhesive active agent delivery products.

The new PetVivo medical device facility will serve as the primary location for PetVivo medical device operations. These operations provide manufacturing capabilities to produce up to 500,000 syringes of Kush that could produce greater than$100 million in revenue annually. The facility includes more than 600 square feet of state-of-the-art ISO 5, ISO 7, and ISO 8 cleanroom space.

Last month, PetVivo Holdings announced the entry into a sponsored research agreement with Colorado State University (CSU) College of Veterinary Medicine and Biomedical Sciences. This to engage in a clinical study involving the treatment of osteoarthritis in canines via the administration of PetVivo’s proprietary medical device, KUSH®. Dr. Felix Duerr, DVM, Associate Professor of Small Animal Orthopedics, will serve as Principal Investigator for the research project. Dr. Duerr established and now oversees CSU’s Orthopedic Medicine and Mobility program.

PetVivo Holdings, Inc. (PETV), closed Monday’s trading session at $3.70, off by 7.50%, on 13,068 volume. The average volume for the last 3 months is 11,111 and the stock's 52-week low/high is $0.122199997/$4.1999998.

Westwater Resources, Inc. (WWR)

Nasdaq, The Globe and Mail, Junior Mining Network, StockNews, Stocktwits, Investors Place, Investors Observer, MarketWatch, Energy and Capital, Wealth Daily, CEO.ca, Business Insider, Stockhouse, MarketBeat, Finviz, Morningstar, YCharts, GuruFocus, Netcials, Businesswire, Barchart, Market Screener, Simply Wall St, TMX.com, Stockopedia, Fintel, and Seeking Alpha reported earlier on Westwater Resources, Inc. (WWR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Westwater Resources, Inc. is an energy materials development company. Its battery-materials projects include the Coosa Graphite Project-the most advanced natural flake graphite project in the contiguous United States-and the associated Coosa Graphite Deposit situated across 41,900 acres (approximately 17,000 hectares) in east-central Alabama. The Company previously went by the name Uranium Resources, Inc. It changed its name to Westwater Resources, Inc. in August of 2017. Established in 1977, Westwater Resources is headquartered in Centennial, Colorado. The Company’s shares trade on the Nasdaq Capital Market (NasdaqCM).

Westwater Resources’ battery graphite business serves the green energy storage sector. On September 8, 2020, Westwater Resources announced that it reached an agreement to sell its uranium business so that it could dedicate all of its available resources to the development of its graphite business and the Coosa Graphite Project. The expectation is that pilot plant operations will produce ULTRA-PMG™, ULTRA-DEXDG™, and ULTRA-CSPG™ in quantities that facilitate qualification testing at potential customers.

Pertaining to the Coosa Graphite Project, Westwater’s plan is to permit, develop, and operate the mine starting in 2028. In the meantime, the Company plans to construct the graphite processing facilities in 2021/2022 and start up on purchased non-Chinese feedstock and make graphite products for all battery kinds.

Earlier this month, Westwater Resources provided an update on progress at its pilot plant operations at Dorfner Anzaplan’s facilities near Amberg, Germany, and at facilities in Frankfort, Germany; Chicago, Illinois; and Buffalo, New York. The expectation is that this combined effort will produce a total of greater than 10 metric tonnes of three trademarked Westwater Resources battery-grade graphite products: ULTRA-PMG™, ULTRA-CSPG™, and ULTRA-DEXDG™, which were earlier produced at a bench scale.

Graphite is an important material and is in smartphones, laptops, cars, as well as smoke detectors and flashlights. Graphite is what makes lithium ion batteries work and provides performance enhancements for all other kinds of batteries.

The battery graphite market is growing rapidly. The growth is worldwide, and there is very little battery graphite produced outside of China.

Westwater Resources, Inc. (WWR), closed Monday’s trading session at $5.27, off by 1.8622%, on 2,498,673 volume. The average volume for the last 3 months is 15,929,631 and the stock's 52-week low/high is $0.25/$14.50.

Ascent Solar Technologies, Inc. (ASTI)

Zacks, Microcap Daily, Stocktwits, CSIMarket, Stock of the Week, Infront Analytics, Investing.com, The Wolf Of Penny Stocks, Ready Ratios, OTC.Watch, Morningstar, InvestorsHub, Economies.com, Equities.com, Nasdaq, Insider Financial, Dividend Investor, Proactive Investors, Stockwatch, Simply Wall St, Seeking Alpha, GuruFocus, Stockhouse, Green Leaf Pot Stocks, TradingView, Wallet Investor, and YCharts reported beforehand on Ascent Solar Technologies, Inc. (ASTI), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Ascent Solar Technologies, Inc. is a developer and manufacturer of state-of-the-art, lightweight, and flexible thin-film photovoltaic (PV) solutions. It designs, manufactures, and sells PV integrated consumer electronics and portable power applications for commercial and military users. The Company markets and sells its products via distributors, value added resellers, as well as e-commerce companies.

Established in 2005, Ascent Solar Technologies is based in Thornton, Colorado, where its Research and Development (R&D) and its 30 MW nameplate production facility are. Ascent Solar modules were named as one of the top 100 technologies in both 2010 and 2015 by R&D Magazine. In addition, they were named one of TIME Magazine's 50 best inventions for 2011.

The Company is a developer of thin-film PV modules using flexible substrate materials that are more versatile and sturdy than traditional solar panels. The technology represents the leading edge of flexible power. It can be directly integrated into consumer products and off-grid applications, and also other aerospace applications. Ascent Solar Technologies provides solar solutions from bare modules to finished goods and everything in between.

The Company has its patented 3-step manufacturing process. Step 1 is thin-film deposition. Step 2 is monolithic integration. Step 3 is final assembly. Ascent’s inventive monolithic integration process enables the highest level of efficiency, durability and weight savings. This represents the potential to transform the way solar power can be used in everyday life. The Company’s solar technology and power solutions are for remote locations and extreme environments. Regarding its IP (Intellectual Property), Ascent Solar Technologies has more than 80 U.S. and International issued patents and published patent applications.

Ascent develops and manufactures its innovative CIGS (Copper-Indium-Gallium-Selenide) photovoltaic technology on a flexible, plastic substrate. The design of these panels are to convert sunlight into electric power through laying a thin layer of these four elements onto a plastic backing.

The Company is a leader in the CIGS field. It is the only manufacturer commercially producing CIGS solar on a plastic substrate with monolithic integration, which is an important differentiator for the Company.

Ascent Solar Technologies, Inc. (ASTI), closed Monday’s trading session at $0.0076, up 171.4286%, on 1,076,638,711 volume. The average volume for the last 3 months is 101,028,385 and the stock's 52-week low/high is $0.000000999/$0.003.

CannaPowder, Inc. (TLFE)

TeleTrader, Street Insider, Last10k, Wallet Investor, Market Screener, InvestorsHub, Stockhouse and Simply Wall St reported beforehand on CannaPowder, Inc. (TLFE), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

CannaPowder, Inc. is developing innovative nanometric cannabis powders. These are to enable cannabis users, whether for recreational or medicinal purposes, to more efficiently interact with the endocannabinoid mechanism. Nanometric powder is a pioneering drug delivery mechanism that is highly efficient. The Company previously went by the name Smart Energy Solutions, Inc. It changed its name to CannaPowder, Inc. in December of 2017. Established in 1999, CannaPowder has its head office in Tel Aviv, Israel.

Nanometric powders have considerable advantages over non-nanometric powders and plant oils. These include effective production processes and acceptable dosage forms, decreased dosage requirement, improved absorption, bioavailability and efficacy, and relatively long shelf life. Nanometric powders are already being used for other plants by some generic pharmaceutical companies, with different FDA (Food and Drug Administration) approved drugs, and by other industries such as cosmetics, beauty products and others.

The technology that is the foundation CannaPowder’s delivery system was developed at The Hebrew University of Jerusalem, an international leader in academic research and development of medical cannabis, under the leadership of Dr. Shlomo Magdassi, Professor of Chemistry at the Center for Nanoscience and Nanotechnology.

CannaPowder, having verified the technology, entered into an exclusive global license for the process with Yissum Research and Development Company. This is the technology transfer arm of The Hebrew University of Jerusalem. The Company has engaged Professor Magdassi to continue oversight of its work to commercialize the technology on an industrial scale. In addition, CannaPowder entered into an agreement with Univo Pharmaceutical Ltd., to process cannabis on its behalf. Univo has one of the very few processing licenses issued in Israel.

The technology involves the use of a Nanometric powder formulation consisting of a cannabinoid oil and other materials that are dispersed in water controlled by a number of repeatable parameters. The oil concentration can be increased or decreased in the process and can include permeation enhancers for increasing bioavailability. Moreover, it can be formulated in different pharmaceutical delivery systems including capsules, tablets, creams, as well as aqueous dispersions.

CannaPowder, Inc. (TLFE), closed Monday’s trading session at $1.00 and the stock's 52-week low/high is $1.00/$1.00.

Northsight Capital, Inc. (NCAP)

Awesome Penny Stocks, OTC Markets, InvestorsHub, GuruFocus, Insider Monkey, Stockopedia, Equity Clock, Marketwired, The Street, Equities, MarketWatch, Barchart, WhaleWisdom, Stockhouse, Simply Wall St, and Uptick Newswire reported previously on Northsight Capital, Inc. (NCAP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Northsight Capital, Inc. consists of a portfolio of online Cannabis-related websites that are undergoing development and operated by the Company. These sites incorporate numerous facets of the Cannabis industry. The Company is transitioning into two sectors. One is the Bitcoin ATM service industry. The other is its modern cannabis advertising and media platform. Northsight Capital is headquartered in Scottsdale, Arizona.

Northsight Capital does not sell or distribute any cannabis products. The Company is looking to acquire digital or publishing companies in the space. It has its 420Careers.com. This is a leading job site in the Cannabis space.

Northsight Capital also has its WeedDepot.com. This website provides consumers with a geo-targeted map directory of medical and recreational dispensaries, head shops, doctors, attorneys and more within the Cannabis industry. Weed Depot has a whole platform of content suited for every aspect of advertising and marketing to consumers from all businesses in the cannabis industry.

Northsight Capital earlier acquired Crush Mobile, LLC. Crush Mobile has developed a group of dating sites with a presence in the Latino, Israeli, and African American communities. Crush Mobile is a part of the Company’s growing media group. Crush Mobile has incorporated into its dating applications suite Northsight Capital's "Joint Lovers" dating app that centers on the Cannabis space.

Northsight Capital reached an agreement in principal in 2018 to be the exclusive distributor of CBD products for SeniorsCBD, a brand of Seniors for CBD. Northsight Capital and Seniors for CBD signed an agreement in principal to create the first CBD product line specifically for the seniors’ market. Seniors for CBD (www.SeniorsforCBD.com) is a leader in the industry for educating and informing seniors on the continuing research on medical marijuana and CBD through bringing current news each day to their followers.

This past December, Northsight Capital announced that it launched its new enhanced cannabis careers web site, www.420Careers.com. This site first launched in 2010. It is considered one of the foremost career sites in the cannabis arena. The site has been updated with many new more user-friendly features. These features make it easier for job seekers to post their resumes and also makes it easier for employers to access them. The 420Careers site has 2,000 to 3,000 visitors a day and roughly 1 million-page views per month.

Recently, Northsight Capital announced an agreement in principal to be the master distributer of 3 exclusive lines of CBD products. The initial orders will be shipped early next month. The lines include earlier announced SeniorsCBD, specializing in formulas specifically for seniors, LiquidMD, a CBD infused water, LiquidMD for pets, and Nature Grown CBD, Northsight’s generic brand.

The Company is expecting to receive the initial shipment of its CBD products on or about the first week of March. First distribution will be through Northsight's broad online media presence and also independent sales and distribution outlets.

Northsight Capital, Inc. (NCAP), closed Monday’s trading session at $0.0002, up 100.00%, on 406,900 volume. The average volume for the last 3 months is 163,974 and the stock's 52-week low/high is $0.000000999/$0.001799999.

Nautilus Minerals, Inc. (NUSMF)

OTC Markets, PennyStockTweets, Stockhouse, Equities, Marketwired, InvestorsHub, Barchart, Junior Mining Network, The Street, MarketWatch, and YCharts reported previously on Nautilus Minerals, Inc. (NUSMF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Nautilus Minerals, Inc. is the first company to explore the ocean floor for polymetallic Seafloor Massive Sulphide (SMS) deposits. Nautilus is developing a production system utilizing existing technologies adapted from the offshore oil and gas industry, dredging and mining industries to enable the extraction of these high-grade SMS systems on a commercial scale.

Nautilus Minerals has offices in Brisbane, Australia; Canada; and in Kavieng, New Ireland, Papua New Guinea, and Nuku'alofa, Tonga, South Pacific.

A seafloor resource exploration business, Nautilus explores and develops the ocean floor for copper, gold, silver, and zinc SMS deposits. Furthermore, the Company explores for manganese, nickel, copper, and cobalt nodule deposits. Nautilus has its copper-gold project named Solwara 1. It is under development in the territorial waters of Papua New Guinea (PNG).

The Solwara 1 deposit sits on the seafloor at a water depth of about 1600 meters. Solwara 1 contains a copper grade of approximately 7 percent. This compares with land-based copper mines, where the copper grade today averages 0.6 percent.

Gold grades of substantially more than 20 g/tonne have been recorded in some intercepts at Solwara 1. The average grade is roughly 6 g/tonne. Moreover, the Company holds highly prospective exploration acreage in the western Pacific (granted and under application), and in international waters in the Central Pacific.

Nautilus Minerals is currently negotiating the terms of an agreement with arm's length third parties. This would involve the establishment of a new joint venture company (the Vessel JV) to be owned by the third parties and Nautilus’ subsidiary, Nautilus Minerals Niugini Limited (NMN).

The purpose of the Vessel JV would be to fund the acquisition of the Production Support Vessel (PSV) that Nautilus had previously arranged to be obtained through MAC Goliath Pte Ltd (MAC) and the integration expenses of installing the mining equipment on the PSV. The Vessel JV would own and operate the fully integrated PSV.

Recently, Nautilus Minerals announced that it and Deep Sea Mining Finance Ltd. agreed to extend the maturity date of the existing secured loan facility that is currently due on February 8, 2019, for 28 days ending on March 8, 2019.

Nautilus continues to seek short and long term funding solutions. This is while assessing its options, including different restructuring options. Negotiations with various third parties continue.

Nautilus Minerals, Inc. (NUSMF), closed Monday’s trading session at $0.0028, up 154.5455%, on 357,000 volume. The average volume for the last 3 months is 1,368,473 and the stock's 52-week low/high is $0.0003/$0.023499999.

Spotlight Innovation, Inc. (STLT)

Penny Picks, Profitable Trader Authority, Damn Good Penny Picks, OTCtipReporter, Beacon Equity Research, SuperStockTips, InvestorSoup, PennyStockScholar, Journal Transcript, PennyStockLocks, StockRockandRoll, Elite Stock Alerts, Penny Stock Finder, Stock Preacher, Penny Stock Craze, Stock Commander, TopPennyStockMovers, Ceocast News, and Real Pennies reported on Spotlight Innovation, Inc. (STLT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Spotlight Innovation, Inc. advances technologies designed to address rare, emerging, and neglected diseases. The Company identifies and acquires rights to unique and proprietary platform technology candidates. Its emphasis is on cancer drugs and related treatment therapies, solutions for infectious disease, and other specialty and distinctive opportunities.

The Company’s subsidiaries include Celtic Biotech and Caretta Therapeutics, LLC. Spotlight Innovation is based in Urbandale, Iowa.

Spotlight Innovation’s mission is to considerably impact patient health through advancing new platform biotechnologies for cancer and infectious disease. Access to platform technology candidates’ is attained through its extensive relationships with numerous leading academic institutions and other sources. Spotlight provides value-added development capability and funding to expedite development progress.

The Company’s development pipeline includes product candidates for cancer, chronic pain, spinal muscular atrophy (SMA) and Zika virus infection. Spotlight works to acquire the rights, via acquisition, license, or otherwise, to innovative and proprietary Platform Technology Candidates. Additionally, it works to provide value-added development capability and funding to achieve fast IND approval to commence human clinicals for targeted Platform Technology Candidates.      

Spotlight Innovation has obtained from the Florida State University Research Foundation (FSURF) exclusive global rights to develop and commercialize certain compounds for the treatment of viral infections. This includes the Zika virus infection.

Spotlight Innovation subsidiary Caretta Therapeutics has its chronic pain relief product Venodol Roll-on. This product is a non-opioid, non-addictive topical analgesic formulated to provide long-lasting relief from chronic pain associated with inflammation.

Spotlight Innovation has started Part 2 of a Phase 1 Cancer Trial. Its subsidiary, Celtic Biotech, started Part 2 of its Phase I dose escalation safety study, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. Contract Research Organization (CRO) ImmunoClin Ltd. is supervising the study conduct.

Spotlight Innovation has entered into a multi-year partnership agreement with Hip-Hope, Inc. (Des Moines, Iowa-based), an organization committed to using arts and culture to promote, advocate and support hope for at-risk youth wherever symptoms of hopelessness are widespread.

As part of this partnership, Spotlight Innovation is the title sponsor for Hip-Hope’s 2018 “#kidslivesmatter FUNraiser Challenge” to take place August 3, 2018, at the 7 Flags Event Center in Clive, Iowa. The annual event is a youth empowerment campaign. The design of it is to build kids’ character, physical health, as well as self-esteem.

Recently, Spotlight Innovation announced that Company research collaborator Professor Kevin Hodgetts was awarded a grant of $300,000 by the nonprofit organization Cure SMA for the project Pre-Clinical Development of LDN-5178 for the Treatment of SMA.

Spotlight Innovation holds an exclusive, worldwide development and commercialization license from Indiana University Innovation and Commercialization Office for LDN-5178 and a group of related compounds. This includes STL-182.

Spotlight Innovation, Inc. (STLT), closed Monday’s trading session at $0.025, up 1090.48%, on 1,812 volume. The average volume for the last 3 months is 3,447 and the stock's 52-week low/high is $0.000000999/$0.035.

SETO Holdings, Inc. (SETO)

Penny Stock Tweets, OTC Markets, 4-Traders, WalletInvestor, InvestorsHub, and Stockhouse reported on SETO Holdings, Inc. (SETO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A development stage company, SETO Holdings, Inc. provides healthcare services. Based in Hanover, Maryland, the Company focuses on three main sectors. These are Health, Education and Clean Energy.

SETO analyzes markets, operations, and guides businesses through the challenges they face. Regarding Healthcare, the Company provides hearing health care and distributes hearing aids via 15 hearing clinics in Maryland and Virginia. Established in 2004, SETO lists on the OTC Markets.

Advanced Hearing Group is the Company’s principal audiology and hearing Services Company. Advanced Hearing Group has clinics across the U.S. Mid-Atlantic region. Seto's Health (SH) division works to expand the Company’s other health services.

Seto Energy (SAE) promotes alternative energy projects in India. In addition, Seto's Education (SE) division promotes health education to the 50-plus active adult community Seto Life (SL).

SETO is working to expand its existing healthcare services within the U.S. The Company is pursuing the implementation of projects in developing markets, particularly in India. Concerning Clean Energy, SETO is expanding its operations to encompass clean energy in developing markets, again specifically in India.

In January of this year, SETO Holdings announced that its subsidiary entered the cannabis sector, specifically the $US15 billion medical marijuana sector. This represents a significant expansion within the Company's Health Division.

SETO’s plan is to execute Hydroponic farming techniques for the development of cannabis farming and for the development of products derived from medical marijuana cultivation. Additionally, the Company plans to implement financial technology solutions for the fast expanding, multi-billion-dollar cannabis sector.

Recently, SETO Holdings announced its newest hearing clinic in Frederick, Maryland. This clinic will center on pediatric and geriatric patients. This also boosts Seto Hearing Group's (SHG) presence in the market. SETO has partnered with the Department of Aging as the exclusive hearing care provider for its 20 facilities in Baltimore County, Maryland.

SETO Holdings also recently announced it will start the development of medical software. This project is being developed under a subsidiary called Setosoft. Setosoft's software applications will augment the Company’s internal efficiencies and that of other healthcare providers. The design phase has been completed. Setosoft is putting together the team of software engineers to implement the project.

SETO Holdings, Inc. (SETO), closed Monday’s trading session at $0.023, up 90.0826%, on 33,000 volume. The average volume for the last 3 months is 2,011 and the stock's 52-week low/high is $0.010499999/$0.059999998.

Yappn Corp. (YPPN)

SmallCapFinancialWire, PennyStocks24, Shiznit Stocks, Stock Shock and Awe, StockRunway, Orbit Stocks, MyBestStockAlerts, Fast Money Alerts, Penny Stock General, TopPennyStockMovers, SmallCapVoice, Information Solutions Group, and Social Hot Dog reported previously on Yappn Corp. (YPPN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Yappn Corp. is a real-time unique language solutions enterprise that amplifies brand messaging, helps conduct commerce, and provides customer support through globalizing these experiences with its proprietary approach to language. Established in 2010, Yappn provides people and brands the power to be social, conduct commerce, and communicate freely without a language barrier.

Yappn has its headquarters in Markham, Ontario. The Company lists on the OTC Markets’ OTCQB. The Company was previously known as Plesk Corp. It changed its name to Yappn Corp. in March of 2013.

In essence, Yappn approaches the challenge of real-time language translation in a completely innovative manner. The result is enhanced translations based on the context of the content or discussion. Consequently, this substantially improves the translation result. According to Common Sense Advisory, more than 72 percent of consumers say they are more likely to purchase online if the experience is in their preferred language.

Backed by its proprietary technology, Yappn’s advanced algorithms return translation with the correct meaning and context of the message. It does so in real-time. The Company’s system is constructed on an enterprise development methodology. It is hosted on Microsoft’s Azure® cloud-based platform.

Yappn provides products for ecommerce, customer care, enhanced messaging collaboration, and online marketing. Furthermore, the Company provides custom translation solutions to different verticals. These include entertainment, retail, as well as marketing.

Yappn has its e-translation product. This is an advanced product that provides global vendors with the ability to integrate into leading ecommerce marketplace sites.

Yappn offers a complete customizable set of tools to engage consumers in more than 100 languages. Yappn is free for users who want to participate on the Company’s general discussion board, unless otherwise noted.

A user’s language is detected by their browser setting automatically. At the very bottom of the page, a user will find a translator bar with the option to choose many languages. A user selects their language and all Yappn pages immediately translate. Everything a person sees on Yappn is in their language, regardless of the language in which it was initially posted.

Yappn Corp. (YPPN), closed Monday’s trading session at $0.00408, up 85.4545%, on 1,235 volume. The average volume for the last 3 months is 22,483 and the stock's 52-week low/high is $0.000399999/$0.0068.

The QualityStocks Company Corner

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Net Element (NASDAQ: NETE) was featured today in a publication from Green Car Stocks, examining how, as part of a global push to reduce carbon emissions and improve air quality, several governments, cities and states have issued bans against the sale of internal combustion engine vehicles in favor of electric vehicles (“EVs”). Europe undoubtedly leads the race towards electrifying its roads thanks to its ambitious ICE vehicle bans, with at least seven European countries pledging to ban the sale of new ICE vehicles over the next 30 years. Also today, the company was featured in a publication from Green Car Stocks, examining how NETE, which is in the process of transforming its business model to become a pure-play electric vehicle (“EV”) manufacturer through a pending merger with privately-held Mullen Technologies Inc., is poised as the EV sector has seen a sharp uptick in consumer demand and investor interest. To view the full article, visit https://ibn.fm/93wvE

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Monday’s trading session at $12.29, up 0.408497%, on 889,321 volume. The average volume for the last 3 months is 1,517,004 and the stock's 52-week low/high is $1.472/$20.0783996.

Recent News

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has announced the closing of its registered direct offering of 3,116,884 shares of its common stock with a single health care-dedicated institutional investor. Genprex secured gross proceeds of $12 million, before deducting commissions and estimated expenses, with the offering priced at-the-market under Nasdaq rules at a price of $3.85 per share. To view the full press release, visit http://ibn.fm/1gQH0

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Monday’s trading session at $4.75, up 1.2793%, on 2,301,119 volume. The average volume for the last 3 months is 976,693 and the stock's 52-week low/high is $0.25999999/$7.0300002.

Recent News

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

Large cap technology growth stocks like Amazon and Tesla have seen a massive wave of investor momentum as a result of COVID-19. The resulting overvaluations and decreased momentum in recent weeks, however, are prompting some analysts to recommend a shift back to small cap value investments (https://ibn.fm/FSEQm). LD Micro, a prominent resource to the microcap world, recently covered nearly 250 established and emerging micro-cap companies at its 13th Annual Main Event on December 14-15, 2020. The event was hosted by SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, on Sequire - its virtual events and investor analytics SaaS platform.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Monday’s trading session at $3.12, up 19.084%, on 1,077,485 volume. The average volume for the last 3 months is 94,944 and the stock's 52-week low/high is $1.50999999/$3.79990005.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it was featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers CNS Pharmaceuticals’ Investigational New Drug (“IND”) application for its lead product candidate, Berubicin, for the treatment of Glioblastoma Multiforme (“GBM”). To view the full press release, visit http://ibn.fm/kSVfH

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday’s trading session at $1.85, up 3.9326%, on 2,409,015 volume. The average volume for the last 3 months is 1,029,907 and the stock's 52-week low/high is $1.25820004/$5.61999988.

Recent News

Brain Scientific Inc. (OTCQB: BRSF)

The QualityStocks Daily Newsletter would like to spotlight Brain Scientific Inc. (OTCQB: BRSF).

Brain Scientific Inc. (OTCQB: BRSF) was featured today in a publication from BioMedWire, examining how a recent study reported in “Environmental Science & Technology” outlines a procedure that can be used to not only detect the coronavirus in wastewater samples but also track the rate of infection to know whether the levels are moving down or up.

Brain Scientific Inc. (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. With a mission of modernizing brain diagnostics by employing cutting edge technologies to bridge the widening gap in access to quality care, the company offers two FDA-cleared products that provide next-generation solutions to the neurology market.

The company’s proprietary, clinical-grade neurological devices are supported by its intellectual property portfolio featuring patents in the United States, China and Europe.

Brain Scientific’s first commercialized devices, NeuroCap(TM) and NeuroEEG(TM), are designed to disrupt the current electroencephalogram (EEG) market by offering cost-effective and disposable substitutes to existing solutions, allowing medical professionals to collect diagnostic information quickly.

The company’s goal is to improve diagnostics by leveraging artificial intelligence and machine learning processes to analyze a database of brain readings as a method of detecting seizures and dementia. The company is also working to improve patients’ access to neurological care.

Headquartered in New York, Brain Scientific and its predecessor (and now wholly owned subsidiary, MemoryMD Inc.) was founded in 2015 and went public in 2018.

Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade, easy-to-use neurological devices. The second phase, currently ongoing, aims to create cloud-based, secure infrastructure to transmit patient data between patients and their neurologists. The company’s third phase of development is scheduled for 2021-2022 and is expected to focus on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists.

NeuroCap(TM) – Disposable EEG Headset

The NeuroCap is a disposable pre-gelled EEG headset featuring 22 electrodes and 19 active EEG channels, all adhering to the international 10-20 system. The NeuroCap was FDA-cleared in 2018. The headset can be used for recording EEGs in virtually any setting, including urban and rural emergency departments, neurology clinics, urgent care clinics, ICUs, nursing homes, assisted living facilities and remote clinical research labs.

Through a universal cable adapter, the NeuroCap is compatible with other EEG amplifiers. The cap also works in parallel with Brain Scientific’s NeuroEEG amplifier, initiating EEG studies in less than five minutes.

The company is currently seeking FDA approval for additional features for the NeuroCap, as the device has the potential to fill a gap in EEG testing availabilities during the current coronavirus pandemic: in October 2020, Brain Scientific filed an Emergency Use Authorization (EUA) application. The EUA is required for the rapid distribution of the NeuroCap device to emergency departments, intensive care units and other treatment centers to administer prescriptive EEGs safely on critically ill patients or those suspected of being diagnosed with COVID-19.

With more than 80 percent of hospitalized patients infected with COVID-19 displaying neurological symptoms, the NeuroCap could prove to be a valuable device by offering fast testing with limited contact between technicians and patients.

NeuroEEG(TM) – Miniature and Portable Wireless EEG Amplifier

The NeuroEEG is a compact, portable and affordable wireless EEG amplifier intended for prescription use. The 16-channel, FDA-cleared, clinical-grade device acquires, records, transmits and displays electrical brain activity for patients of all ages.

Both the NeuroCap and NeuroEEG are delivered by MemoryMD Inc., a wholly owned subsidiary of Brain Scientific.

Products in Active Development

Currently, Brain Scientific and MemoryMD are working on leveraging their existing products and drawing from ongoing research to develop and commercialize the next generation of solutions for the brain diagnostics market. The devices under development are being designed to address the following issues:

Routine EEG

  • NeuroCap-8 is an 8-channel EEG cap. The reduced number of electrodes is vital in emergency room situations, where the time it takes to set up the EEG is critical.

Pediatric EEG

  • NeuroCap Pediatric is positioned to become the first disposable and pre-gelled headset available for the pediatric market.

Long-Term Monitoring

  • NeuroCap LTM for adult and pediatric patients is a disposable cap designed to monitor rhythmic and periodic patterns for up to 72 hours, providing essential diagnostic capabilities.
  • NeuroEEG 24 Channel Amplifier is a portable and wireless amplifier with over 24 hours of battery life.

Artificial Intelligence

  • Brain E-Tattoo is a minimally invasive four-channel EEG electrode designed for long-term monitoring.
  • An AI database of brain biomarkers collects data on both normal and abnormal brain data to detect neurological diseases. The goal is for machine learning algorithms to enhance understanding of brain-behavior related to epilepsy, memory dementia and pre-Alzheimer’s diagnostics.

Telemedicine

Brain Scientific is expanding the vision for telemedicine in neurology. The company aims to address the current acute neurologist shortfall (20 states have less than 10 neurologists per 10,000 patients) through the use of teleneurology.

 

Partnership with Marketing Brainology

Brain Scientific has a longstanding partnership with Marketing Brainology, a neuromarketing firm using neuroscience approaches to understand consumer behavior. In 2019, Marketing Brainology conducted a study using NeuroCap and NeuroEEG to determine the most effective Super Bowl commercials.

“Thanks to Brain Scientific’s NeuroCap and NeuroEEG, we are able to better understand the art and science of the human decision-making process,” Michelle Adams, Ph.D, Founder of Marketing Brainology, stated in a news release.

In April 2020, Marketing Brainology again conducted a study leveraging Brain Scientific’s disposable EEG cap to determine how brains were reacting to COVID-19 messaging. Subjects were presented with multiple media impressions, and Marketing Brainology analyzed their responsive biomarkers. The results identified the most effective messaging for engaging with an audience during a crisis.

Market Outlook

The current global market for EEG devices is estimated at $956.1 million. It is expected to rise with a CAGR of 8.7% from 2019 to 2026, reaching $1.6 billion in value by 2026, according to Grandview Research.

In total, there are approximately 6,150 hospitals in the U.S., according to the American Hospital Association. Critically, though, just 254 of those hospitals are certified Level 4 Epilepsy centers with 24/7 EEG coverage. Since very few non-Level 4 centers have extensive EEG tech coverage, this creates a significant opportunity for Brain Scientific to bridge the gap by providing over 5,900 hospitals with lower cost amplifiers and disposable EEG caps.

The company also see opportunities to work with other businesses, such as EEG manufacturers hoping to package Brain Scientific’s solutions with their products, which could greatly expand Brain Scientific’s addressable target market.

Management Team

Dr. Baruch “Boris” Goldstein, Ph.D., is co-founder and Chairman of Brain Scientific. He is a seasoned executive with a proven talent for aligning global business strategies with established and emerging management teams. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital for the development of innovative companies and startups in diverse industries, including financial services, biomedicine, alternate energy and new materials, as well as groundbreaking work in artificial intelligence. His recent achievements include important advancements in neurology and unlocking the potential of AI correlations and machine learning applied to life sciences and medical research. He built a suite of first-to-market companies as a technology-oriented leader, including Ryah Medtech, Brain Scientific, GrapheneCA, E-Forex and Intelligent Video Systems. He also co-founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics.

Dr. Nikolay Kukekov, Ph.D., is a Director of Brain Scientific and a partner at HRA Capital. Before joining HRA Capital, Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research. His scientific background includes a bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder. He earned his Ph.D. in neuroscience from Columbia University – College of Physicians and Surgeons in New York.

Stuart Bernstein is the company’s Vice President of Marketing. He was recently named to the role after spending the first part of his professional career in senior technical management roles with Fortune 500 companies such as NCR (NYSE: NCR), IBM (NYSE: IBM) and Control Data Corp. He was the CEO of BioSignal, an EEG medical device company. He is also a co-founder of several software engineering and telemedicine firms. One of them, Brain Saving Technology, is now Specialist on Call (SOC Telemed) – a leading telemedicine company that powers over 850 facilities for teleneurology, telepsychiatry and critical care telemedicine with over 200 physicians.

Brain Scientific Inc. (OTCQB: BRSF), closed Monday’s trading session at $1.00, up 14.9425%, on 6,382 volume. The average volume for the last 3 months is 3,462 and the stock's 52-week low/high is $0.100000001/$3.00999999.

Recent News

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF)

The QualityStocks Daily Newsletter would like to spotlight GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF).

As the metal exploration boom elevates the junior mining industry's outlook, Canada-based GoldHaven Resources (CSE: GOH) (OTCQB: GHVNF) seems well positioned to leverage the favorable environment that industry experts forecast for 2021 (https://ibn.fm/tFPOm). In a panel discussion hosted by Mines and Money, the leading international event series for capital-raising and mining investment, Jessie Chen of Long State Investment asserted that she expects a bright future for junior mining companies over the next 12 to 18 months. Also today, the company was featured in a publication from MiningNewsWire, examining how, Codelco, located in Chile and the biggest producer of copper in the world, has developed sustainability plans in various areas of action for its projects and operations. The plans include the mine’s aim to reduce carbon emissions by 70%, recycle 65% of its industrial waste and decrease the consumption of inland water by 60% — all by the year 2030.

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (formerly Altum Resources Corp.), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, recently announced its entry into agreements to acquire seven advanced gold projects in the Maricunga Gold Belt of Chile that hosts over 100 million ounces of gold within the last 10 years.

Chilean Gold Properties Being Acquired

On April 17, 2020, GoldHaven Resources entered into an agreement to purchase a 100% interest in two gold projects located in the Maricunga Gold Belt of Northern Chile. The first property, Rio Loa, is located 25 kilometers south of Gold Fields Ltd.’s Salares Norte, where, this year, a five-million-ounce discovery was made. The second property, Coya, is located only 10 kilometers east of the Kinross La Coipa open pit mine, which has produced over 7.5 million ounces of gold to date.

Rio Loa Project

Initial geophysical studies of the Rio Loa site have exposed highly anomalous ardennite and lead values, a key characteristic of gold mineralization within silicified resistive bodies. The studies have also produced initial findings which are similar to those seen at contiguous mines, such as Salares Norte (operated by Gold Fields), which has over five million ounces in estimated gold deposits.

The potential economics for the site look particularly promising when taking the unit costs at the neighboring Salares Norte mine into account. Gold Fields has estimated that its production AISC (all-in sustainable costs) will approximate $552 per ounce and have forecast a 2.3-year payback period for its initial investment, assuming a $1,300 per ounce gold price.

Coya Project

The Coya site is located within close proximity to one of the richest and largest epithermal gold and silver districts in Chile and is in close proximity to active mining sites, specifically the La Coipa mine owned by Kinross. A study carried out in 2017-2018 on the Coya site of 796 rock chip samples found favorable gold and silver values, in some cases ranking as high as 764 grams/tonne of gold and 719 grams/tonne of silver – values which are near certain indicators of potential gold and silver deposits. The La Coipa mine (Kinross) has produced over 6.9 million ounces of gold to date.

On August 11, 2020, GoldHaven Resources acquired five potential gold projects in the Maricunga Gold Belt of Northern Chile. The Maricunga hosts discoveries within the last 10 years of over 100 million ounces of gold and over 450 million ounces of silver. These newly acquired properties are in close proximity to seven other mines, which possess an estimated aggregate of 81 million ounces of gold in total reserves.

GoldHaven’s five new projects cover a total area of approximately 22,600 hectares, or 226 square kilometers, located in the northern portion of the Maricunga Belt in proximity to the 5 million-ounce gold equivalent Salares Norte project owned by Gold Fields. Gold Fields announced in April 2020 its intention to proceed with the development of Salares Norte at a cost of $860 million, with a $138 million expenditure budgeted for 2020.

The Maricunga Belt extends approximately 150 kilometers north-south and 30 kilometers east-west, straddling the border between Chile and Argentina. This region hosts known mineral resources of more than 100 million ounces of gold, 450 million ounces of silver and 1.3 billion pounds of copper.

The Maricunga project’s opportunity came about as a result of a $150 million initiative launched by the Chilean Economic Development Agency (“CORFO”), with the objective of encouraging exploration and mining prosperity in Chile and strengthening Chile’s position as a world leader in the sector.

As part of CORFO’s program, a total of $15.3 million was given to private equity fund IMT Exploration to evaluate 403 projects, beginning in 2011. This led to a generative program carried out from 2016 to 2019, resulting in 126 potential epithermal targets from which 57 field evaluations were made. Due diligence work followed on 19 of these. Work programs were then conducted, including geological mapping, rock and soil sampling and TerraSpec (PIMA) analyses on geochemical grids for alteration mapping, and, as a result, the five high-priority Maricunga projects were identified. No drilling has been carried out on any of the Maricunga projects.

Securing Financing for Upcoming Operations

In conjunction with its announcement regarding its acquisition of five Chilean mining interests, GoldHaven Resources also detailed plans for a non-brokered private placement of 11.5 million units at a price of $0.35 per unit, for gross proceeds of $4,025,000. Each unit will consist of one share of the company and one warrant, the latter of which can be exercised to acquire an additional share of the company for a period of 18 months from the date of issuance at a price of $0.50 per share. Net proceeds from the offering are intended to be used to fund general expenses, as well as exploration and drilling of its mineral properties.

Gold Prices Hit Record High in 2020

Gold prices have been on a remarkable run in 2020, breaking above $2,000 per ounce for the first time on record. Having begun the year at $1,515 per ounce, the precious metal has seen a huge surge on the back of widespread economic uncertainty stemming from governments’ worldwide propensity to expand the money supply, from the reduction of the value of the U.S. dollar as expressed by the decrease in the U.S. dollar index, and from the very real economic effects of the COVID-19 pandemic.

Global central banks have carried out 144 interest rate cuts thus far in 2020, reducing rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures has prompted a number of investment banks to boost their near-term outlooks for gold prices, with Bank of America raising its 18-month gold price target to $3,000 per ounce (http://nnw.fm/PQJtc).

Leadership Team

David Smith, President, CEO and Director, has been immersed in the mining industry for the last eight years, working in corporate development and finance. Prior to GoldHaven Resources, Smith cofounded a multifaceted real estate development and sales company, which has now been in operation for over 35 years. He also cofounded two successful environment-focused companies listed on the Toronto Stock Exchange. Both companies were sold independently and returned a significant profit for shareholders.

Darryl Jones, Chief Financial Officer, is a finance executive and CPA with over 30 years of public company and project buildout experience. Most recently, Jones served as the CFO of Lupaka Gold Corp., retiring in June 2018. Prior to that, Jones serves as CFO of Corriente Resources, which was sold to CRCC-Tongguan in May 2010 for C$680 million.

Patrick Burns, VP Exploration and Director, is a Canadian geologist with over 40 years of experience throughout the Caribbean and Central and South America. He played a direct role in the discovery of the Escondida porphyry copper deposit in Chile and has been involved in publicly traded mining companies, predominantly in Chile, for 35 years.

Marla Ritchie, Corporate Secretary, brings over 25 years of experience in public markets to the GoldHaven team. Throughout this time, she has worked as an administrator and corporate secretary specializing in resource-based exploration companies. Currently, Ritchie is the corporate secretary for several companies, including International Tower Hill Mines Ltd. and Trevali Mining Corp.

Gordon Ellis, Director; has over 50 years’ experience in mining and resource development. A professional engineer and entrepreneur, he has held multiple senior management and director roles with public mining companies, as well as a multi-billion-dollar ETF fund. Ellis holds an MBA in international finance and a Chartered Directors designation.

Scott Dunbar, Director is a professor and head of multiple departments at the University of British Columbia, including mineral extraction and mining innovation, as well as mining engineering. He has been involved in projects around the world in regard to mining exploration, geotechnical engineering and mine design. Dunbar received his PhD in geophysics and civil engineering from Stanford University.

GoldHaven Resources Corp. (OTCQB: GHVNF), closed Monday’s trading session at $0.5, up 7.9914%, on 88,600 volume. The stock's 52-week low/high is $0.109999999/$0.800000011.

Recent News

Innovative Payment Solutions Inc. (OTCQB: IPSI)

The QualityStocks Daily Newsletter would like to spotlight Innovative Payment Solutions Inc. (OTCQB: IPSI).

The impact of COVID-19 has been seen and felt far beyond the health-care industry, reaching into sectors that may not seem to be relatable. Yet the global pandemic has fueled the development and acceptance of digital technologies that offer the security and stability the world is looking for right now. One of those technologies — blockchain — seems particularly well suited for this time and place, where Innovative Payment Solutions (OTCQB: IPSI) could make a real difference in unbanked and underbanked communities globally.

Innovative Payment Solutions Inc. (OTCQB: IPSI) is a digital payment technology service company offering cutting-edge solutions for consumers and service providers. It is focused on building a 21st century payment platform based on its proprietary fintech payment architecture.

Incorporated in 2015 and headquartered in Northridge, California, the company has spent the last five years perfecting its payment platform through its operations in Mexico, which still facilitate over two million users.

IPSI’s new business structure will use the latest technology, including blockchain and an e-wallet, to provide consumers the ability to make payments worldwide. The company’s innovative ecosystem will include multiple devices, such as POS terminals, mobile applications and self-service kiosks, offering alternative payment methods to meet the needs of unbanked and underbanked consumers.

IPSI Kiosk Platform

The IPSI Kiosk platform strategy aims to provide simple payment solutions and low-cost financial services for consumers and businesses. These kiosks offer access to digital payments for the unbanked and underbanked, allowing for remittance, merchant payments, microloans and other financial services.

The kiosk enables new features and transaction modules to be added and implemented easily, leveraging a flexible, open architecture to minimize costs. Current services provided by the kiosks include bill pay and cellphone top-up. Additional features are currently in development, including payday loans, gaming, auto insurance, title loans, lottery, international remittance, a mobile app and an e-wallet.

Already linked to Mexico’s largest service providers, the IPSI network is expected to add over 150 services for payment, including mobile networks, cable providers, home lenders, banks and microlenders. In 2019, IPSI’s kiosk network processed roughly 4.5 million transactions in Mexico totaling over $17 million.

The company currently has 50 kiosks that it intends to install at retail locations in Southern California. It also plans to deploy kiosks in other states.

IPSI Kiosk Channel Value

The IPSI Kiosk provides value for businesses and consumers.

For businesses, the IPSI Kiosk:

  • Serves as an additional revenue source;
  • Attracts new traffic and potential customers;
  • Offers remote software updates and monitoring, making the kiosks low maintenance;
  • Is easy to use, with little need for customer service intervention; and
  • Requires minimal staff training and overhead.

For consumers, the IPSI Kiosk:

  • Offers a more comfortable alternative for making payments for cash-dependent unbanked individuals and those uncomfortable with online payments and
  • Is accessible 24/7 for bill payment services.

The IPSI Kiosk also provides add-on services that further its value proposition for both businesses and consumers. These include second screen and targeted advertisement options, payday loans, check deposits, prepaid cards and checkout services.

IPSI Coin

IPSI is currently working on plans to launch its own stable IPSI Coin and has retained Horizons Law and Consulting Group to advise on its stable coin creation. The company plans for IPSI Coin to be backed by the U.S. dollar and administered by an independent custodian to ensure transparency and stability.
The creation of the coin will enable customers to send payments directly to over 200 service providers in Mexico and transfer funds in a matter of minutes via the self-service kiosks to be implemented in Southern California.

“The fintech industry is undergoing a massive shift with the introduction of artificial intelligence, everchanging distribution models, fee diversion and digital payments,” IPSI CEO William Corbett stated in a news release (https://ibn.fm/wwtBV). “We are focused on providing a comprehensive solution in the digital payment arena for those who need it most. Our goal is to provide the millions of unbanked and underbanked as well as banked consumers in California, a cost efficient and convenient method to make payments and remittances with instant settlement.”

Digital Payment Market Outlook

In 2018, the global digital payment market was estimated at $43.5 billion. It is expected to register a CAGR of 17.6% through 2025, reaching a forecast market size of $132.5 billion, according to Grandview Research (https://ibn.fm/pLTUt).

The growth is expected to be led by expanding use of smartphones, e-wallet payment solutions and the introduction of unbanked payment solutions to the market, offering companies such as IPSI significant opportunities for expansion.

Management Team

William Corbett is the CEO and a Director of IPSI. He has 30 years of experience financing and advising development and growth stage tech and biotech companies. Before IPSI, he was the founder and CEO of California-based Digital Power Lending. Corbett gained experience as a managing director during his time with Paulson Investment Co. and in senior banking and top producer roles at Lehman Brothers and Bear Stearns. He was a co-founder of the San Francisco and PIPE pioneer boutique investment bank, The Shemano Group. He has raised over $2 billion during his extensive career.

Andrey Novikov serves as IPSI’s Chief Technical Officer and Chief Operating Officer. He is the former VP of Global Business Development of Qiwi PLC (NASDAQ: QIWI). Leveraging extensive knowledge of the industry, Novikov played a lead role in the development of Qiwi startups in China, Mexico, India, Brazil, Argentina, Chile, Peru and other countries.

James W. Fuller holds a Director position at IPSI. He is the former chairman of San Francisco think tank Pacific Research Institute. He is a board member for The International Institute of Education, a member of the Pacific Council for International Policy, and a former member of the Committee of Foreign Relations and the board of trustees of the University of California – Santa Cruz. He is the former Senior Vice President of the New York Stock Exchange and was responsible for corporate development, marketing, regulation oversight, research, corporate listing and public affairs.

Innovative Payment Solutions Inc. (IPSI), closed Monday’s trading session at $0.0356, up 27.1429%, on 2,087,915 volume. The average volume for the last 3 months is 630,944 and the stock's 52-week low/high is $0.0091/$0.064949996.

Recent News

HempFusion Wellness Inc.

The QualityStocks Daily Newsletter would like to spotlight HempFusion Wellness Inc..

HempFusion Wellness, a leader in the health and wellness cannabidiol (“CBD”) industry, is optimistic about the future of the marketplace despite a 2020 pandemic-driven downturn for hemp and cannabidiol (“CBD”) industries. While products have seen a decrease in sales and farmers have reduced their hemp acreage, there are bright spots on the horizon with both widening legalization and increased awareness as to the benefits of CBD products. To view the full article, visit https://ibn.fm/rXPEh

HempFusion Wellness Inc. is a leader in the health and wellness CBD industry, providing innovative and diversified proprietary formulations utilizing the power of whole-food hemp nutrition.

Invested heavily in regulatory compliance, HempFusion aims to consistently meet and even exceed the high standards required by retailers and consumers – putting safety, quality and consistency first. In support of these efforts, the company is U.S. Hemp Authority Certified and is a current board member of the U.S. Hemp Roundtable, a coalition of leading companies committed to advancing safe hemp and CBD products.

HempFusion reported 1,750 shareholders and $18.3 million in cash as of June 30, 2020 – the second-largest cash position in its sector – with no debt. Looking ahead, the company is currently preparing to launch an IPO directly onto the Toronto Stock Exchange (“TSX”) senior board, where it has already reserved ticker symbol ‘CBD.U’. Learn More About HempFusion Upcoming IPO.

HempFusion is headquartered in Denver, Colorado.

HempFusion’s Proprietary Wellness Portfolio

The diverse product portfolio showcased by HempFusion includes 46 products that are currently on shelves. The company’s leading offerings include HempFusion-owned Biome Labs, HF Labs and Probulin. Due to the time and resources allocated to increasing the compliance of these proprietary products, HempFusion may have a competitive advantage and create additional retail opportunities that are not available for other CBD companies.

HempFusion’s Diversified Revenue Pipeline

HempFusion’s focus and investment into regulatory compliance has opened doors to major food and drug mass or big box retailers that are not available to other CBD companies. This strategic approach includes five distinct channels:

  • Natural Health Retailers
  • eCommerce
  • Big Box / Food and Drug Mass
  • Doctor Practitioner
  • Convenience

HempFusion’s Line of Products

HempFusion’s branded line of products is based on the company’s proprietary Whole Food Panoramic Full-Spectrum Hemp Complex. Each product is condition-specific, targeting needs such as sleep, energy and stress.

All of HempFusion’s products are made from DNA-verified, European Union registered, non-GMO, organic industrial hemp. The company’s offerings span multiple product categories, including:

  • Tinctures and capsules – These offerings make up the most popular product category in the $4 billion U.S. CBD market.
  • OTC topicals – HempFusion is one of the few CBD companies marketing FDA Drug Listed Topicals. The FDA compliance standards ensure that these products meet the standards set by larger national retailers.
  • Condition-specific OTC products – HempFusion has OTC products that are condition-specifically targeted, including:
    • OTC Pain Products – The global pain relief market for topicals is projected to reach $13.3 billion by 2025, with a CAGR from 2018 to 2025 of 7.4%.
    • OTC Eczema Products – The global dermatitis market is projected to reach $13.6 billion by 2026.
    • OTC Acne and Aging/Beauty Products – The global market for beauty and anti-aging products is currently estimated at $1.08 trillion.
    • OTC First Aid and Wound Healing Products – In 2019, the 10 top-selling first aid ointments in the United States generated over $650 million in sales.

Probulin Probiotics and Digestive Enzymes

Probulin Probiotics is a 100% wholly owned subsidiary of HempFusion Wellness Inc. and is currently one of the fastest growing probiotics brands in the United States, according to Spins syndicated data.

The Probulin product line addresses a wide range of consumer needs, including daily care, total care, women’s health and children’s products. The probiotics market represents a growing opportunity, as it is estimated to reach $7 billion globally by 2022.

Because of the diverse offerings of the Probulin line, it serves as HempFusion’s gateway to retailers who may not currently carry CBD products.

This ‘Trojan Horse Strategy’ is intended to allow the company to establish, develop and build relationships among these retailers. By achieving approved vendor status, the company may be able to facilitate faster onboarding times, enabling accelerated access to its CBD products in the future.

HF Labs and Biome Research – Doctor and Practitioner Product Lines

The HF Labs and Biome Research product lines are directed toward doctors and practitioners and cater to hospitals, compounding pharmacies and free-standing dispensaries. With an estimated target market of 28,000+ integrative medical doctors and 70,000+ licensed chiropractors in the United States, these offerings create a unique market opportunity as HempFusion continues to broaden its footprint in the CBD industry.

Research on CBD and Human Safety

HempFusion is one of 12 CBD companies selected to participate in ValidCare’s groundbreaking study regarding CBD and human safety, which is expected to be complete by the end of October 2020. The study is designed to address previous questions from the FDA regarding CBD products.

As part of this study, HempFusion and the other selected companies will be conducting human trials to determine if the daily use of full-spectrum hemp-derived CBD or CBD isolate impacts the human liver.

Management Team

Jason Mitchell, N.D., is the co-founder, Director and CEO of HempFusion. He has over 20 years of experience in the natural products industry and is a naturopathic doctor certified by the ANMCB. Mitchell received his doctorate from the Trinity College of Natural Health and is a member of the American Naturopathic Medical Association and the CNHP. He is an expert in supplemental formations and was responsible for successfully creating and launching over 300 industry-leading products during his 15-year tenure at Country Life Vitamins.

Ian DeQueiroz is the Chief of Brand Strategy & Partnerships and a Director for HempFusion. He is a serial entrepreneur with experience in early-stage cannabis and hemp companies. In 2010, he acquired his first cannabis CO2 extraction company in the United States. DeQueiroz has facilitated the licensing process for many companies in the United States, as well as one of Jamaica’s premier cannabis companies, Epican Medicinals Ltd.

Jon Visser is HempFusion’s Chief Revenue Officer. He has over 25 years of experience in all areas of sales and marketing, with a proven track record of consistently driving growth across all major channels. Visser was previously the Senior Vice President of Sales at Navajo Inc., a multi-national manufacturer/distributor of brands like Pennzoil Automotive Supplies, Piranha Eyewear and Navajo Inc., the largest distributor of trial- and travel-sized health and beauty products in the United States. Visser grew annual sales from $60 million to $128 million in less than three years while at Navajo Inc.

Bruce Valentine Jr. is the Chief Financial Officer of HempFusion. He has a proven track record working with high-growth companies and was named CFO of the Year in 2013 by the Northern Colorado Business Report. Valentine is the former CFO of Otter Products and has over 15 years of financial management experience.

Ola Lessard is the Chief Marketing Officer of HempFusion and is also the President of the U.S. Hemp Roundtable. She has experience in marketing creative and effective brand strategies. She is a former Vice President of Marketing at Barlean’s, an award-winning supplements provider based in Washington.

Nancy Angelini is the Director of the Doctor/Practitioner Channel. She has over 25 years as an active, licensed practitioner. Angelini travels the country as a lecturer and product manager. She is responsible for opening doors to some of the largest doctor/practitioner networks in the United States.

Daniel Brody is the Chief Corporate Officer of HempFusion. He is the co-founder and former Vice President of The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF). Brody has been instrumental in listing multiple world-class cannabis companies, including TGOD, Emblem Corp. and Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF). Before joining the cannabis industry, he spent seven years working at two leading Canadian brokerage firms.


Recent News

chart

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)

The QualityStocks Daily Newsletter would like to spotlight Foresight Autonomous Holdings Ltd. (FRSX).

Foresight Autonomous Holdings (NASDAQ: FRSX) (TASE: FRSX), an innovator in automotive vision systems, has announced its entry into definitive agreements with investors for the purchase and sale of 6,265,063 of Foresight’s American Depositary Shares (“ADSs”), each at a price of $4.15, per a registered direct offering. The company will secure approximately $26 million in gross proceeds before deducting placement agent fees and other estimated offering expenses. To view the full press release, visit http://ibn.fm/s9YgF

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), founded in 2015 and headquartered in Israel, is a technological innovator in automotive vision systems and driver assistance technology. Through its wholly owned subsidiary, Foresight Automotive Ltd., Foresight is engaged in the design, development and commercialization of stereo/quad-camera vision systems and V2X cellular-based solutions for the automotive industry based on 3D video analysis, advanced algorithms for image processing and sensor fusion. The company’s powerful and patented stereoscopic technology is derived from field-proven technology that has been deployed throughout the world for almost two decades.

Foresight’s innovative autonomous driving solutions are based on mature, proprietary stereoscopic image technology that uses two synchronized cameras to mimic human depth perception and produce a three-dimensional image. This 3D image can anticipate possible collisions with other vehicles, cyclists, pedestrians and other obstacles. The technology provides highly accurate real-time alerts about the vehicle’s surroundings while in motion. The systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts.

The company’s patents provide IP protection for its robust and proven proprietary stereoscopic technology, which was developed using the security technology of Foresight’s major shareholder, Magna B.S.P.

Foresight has developed three main products:

  • QuadSight™. This breakthrough detection system sets the bar for autonomous vehicle vision. It features nearly 100 percent obstacle detection with almost zero false alerts and operates optimally under all weather and lighting conditions, including darkness, rain, fog, haze and glare. QuadSight™ is the first quad-camera multi-spectral vision solution of its kind, driven by advanced and proven image processing algorithms. The system consists of two sets of stereoscopic infra-red and visible-light cameras that enable highly accurate and reliable obstacle detection for seamless 24/7 vision.
  • Eyes-On™. This solution uses advanced algorithms for accurate depth analysis and obstacle detection to provide a unique stereo vision Advanced Driver Assistance System (ADAS). It can detect all potential obstacles regardless of shape, form or material, including other vehicles, cyclists, pedestrians and animals. It has an accuracy and reliability of almost 100 percent and near zero false alerts.
  • Eye-Net™. This is a cellular-based accident prevention solution that is designed to provide real-time pre-collision alerts to vehicles and pedestrians. This proprietary system is deployed on smartphones and cloud-based servers operating on existing cellular networks, and it eliminates the need for additional designated hardware. Eye-Net™ is designed to provide a complementary layer of protection to advanced driver assistance systems and extends this protection to road users who are not in direct line of sight. It is optimally designed for both urban environments and high-speed scenarios to provide protection for the most vulnerable road users. On March 28, 2018, Foresight announced that it had completed a successful feasibility study of its Eye-Net™ accident prevention solution involving 120 users of Android and iOS cell phones located across Israel.

In 2017, Foresight sought more opportunities within the international market. The Company signed pilot agreements with three leading car manufacturers in China and completed pilot projects meeting all pre-defined requirements and criteria. In addition, FRSX completed a pilot project with Uniti Sweden.

Studies by the Insurance Institute for Highway Safety continue to emphasize the dramatic reduction in accidents and injury-related crashes reported when vehicles are equipped with collision avoidance systems. A recent study by the Institute states that the rate of single-vehicle, sideswipe and head-on crashes was 11 percent lower in vehicles with the warning systems. More importantly, the study shows collision avoidance technology cut the rates of injury crashes of the same type by 21 percent.

Foresight Autonomous Holdings, Inc. also holds a 32 percent interest in RailVision, a company that develops advanced systems for railway safety and maintenance. RailVision has successfully completed 13 tests in Israel, Germany, Italy and Switzerland in addition to a real-time system test with a European railway operator. Over the course of 2017, RailVision successfully completed rounds of financing totaling $5.8 million and started the process of licensing the system according to European standards.

Haim Siboni is the founder of Foresight and has served as the company’s chief executive officer and director since 2015. Siboni, a passionate entrepreneur, has an extensive background in the marketing and business management sectors in the fields of electronics, video, TV, multimedia, computerized systems, line and wireless telecommunication, design and development of systems and devices, including electro-optic radar systems. He is the founder and CEO of Magna B.S.P., Foresight’s major shareholder and a leading innovator in the field of homeland security surveillance solutions.

Foresight Autonomous Holdings Ltd. (FRSX), closed Monday’s trading session at $4.47, off by 10.9562%, on 28,483,298 volume. The average volume for the last 3 months is 7,680,857 and the stock's 52-week low/high is $0.460999995/$6.4499998.

Recent News

Cybin Inc. (NEO: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN).

Cybin (NEO: CYBN), a mushroom life science company, is set to leverage opportunity amid growing research that demonstrates the significant role psilocybin could play in alleviating symptoms of major depression. According to a recent study conducted by Johns Hopkins Medicine and published in “JAMA Psychiatry,” only two doses of psilocybin accompanied with psychotherapy may lead to significant reductions in symptoms in adults with major depression (https://ibn.fm/ZpmzM). To view the full article, visit https://ibn.fm/QU6P6

Cybin Inc. (NEO: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN), closed Monday’s trading session at $1.89, off by 2.07%, on 147,140 volume. The average volume for the last 3 months is 977,823 and the stock's 52-week low/high is $0.64/$2.50.

Recent News

VistaGen Therapeutics Inc. (NASDAQ: VTGN)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics Inc. (NASDAQ: VTGN).

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in an equity research report by Maxim Group LLC. The piece discusses VistaGen’s strongest positioning yet, based on its pharmaceutical pipeline coupled with financing and a rising mental health pace. To view the full report, visit http://ibn.fm/zbWAX

VistaGen Therapeutics Inc. (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (CNS) disorders.

The company is headquartered in South San Francisco, California, the “Birthplace of Biotechnology,” among the largest cluster of biotechnology companies in the world.

New Generation Medications

VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of VistaGen’s three drug candidates offers significant commercialization potential in multiple large CNS markets.

PH94B

Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B is a first-in-class neuroactive nasal spray that, administered in microgram doses, binds to chemosensory receptors in the nasal passage that trigger neural circuits responsible for suppressing fear and anxiety caused by stressful social or performance situations.

PH94B is currently being developed as an acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). In December 2019, PH94B became the first drug candidate to be granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for development of a treatment for SAD, positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with the anxiety disorder, if planned Phase 3 studies are successful.

A successful Phase 2 program has been completed, and, after achieving consensus with the FDA in mid-2020 that the design of its Phase 3 studies of PH94B in SAD may mirror the design of the highly statistically significant (p=0.002) Phase 2 public speaking study of PH94B in SAD, the company’s preparations for pivotal Phase 3 clinical development of PH94B are underway.

To support Phase 3 development and commercialization of PH94B for anxiety disorders in large anxiety disorder markets in Asia, VistaGen recently entered into a strategic licensing and collaboration agreement with EverInsight Therapeutics, a company formed and currently funded by a large global venture capital firm, CBC Group. The company received a $5 million non-dilutive upfront license payment from EverInsight in August 2020. If Phase 3 development is successful, VistaGen is eligible to receive additional development and commercial milestone payments of up to $172 million, plus tiered royalties on sales of PH94B in Greater China, South Korea and Southeast Asia. VistaGen retains exclusive rights to develop and commercialize PH94B in all other markets.

VistaGen is also assessing potential Phase 2A clinical development opportunities to evaluate PH94B in a range of other anxiety disorders, including:

  • Adjustment Disorder with Anxiety
  • Generalized Anxiety Disorder
  • Postpartum Anxiety
  • Perioperative Anxiety
  • Panic Disorder
  • PTSD

PH10

PH10 is an investigational fast-acting synthetic neuroactive nasal spray with therapeutic potential in a wide range of neuropsychiatric indications involving depression and suicidal ideation. VistaGen is initially developing PH10 as a potential fast-acting, non-sedating, non-addictive new generation treatment of major depressive disorder (MDD).

Upon self-administration, a microgram-level dose of PH10 sprayed into the nose binds to nasal chemosensory receptors that, in turn, activate neural circuits in the brain that lead to rapid-onset antidepressant effects, without side effects, systemic exposure or safety concerns that may be caused by FDA-approved drug treatments for MDD, including oral antidepressants and intranasal esketamine.

In a published exploratory Phase 2A MDD study, PH10 demonstrated rapid-onset and sustained antidepressant effects without the serious psychological side effects and safety concerns of ketamine-based therapy.

Following successfully completed Phase 2A development of PH10 for MDD, the company is currently preparing for a Phase 2B program in MDD.

VistaGen is also assessing the potential for Phase 2A clinical development of PH10 in a range of other depression-related indications, including:

  • Postpartum Depression
  • Treatment-resistant Depression
  • Suicidal Ideation

AV-101

Part of a class of new generation investigational medicine in neurology and neuropsychiatry known as N-methyl-D-aspartate receptor (NMDAR) modulators, AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), a potent and selective NMDAR glycine site antagonist. This drug candidate has the potential to serve as an innovative treatment for MDD and multiple neurological indications where current therapies are unsatisfactory.

VistaGen is currently evaluating AV-101, in combination with FDA-approved probenecid, in a range of neuropsychiatric and neurological indications, with both MDD and Neuropathic Pain already granted Fast Track designation by the FDA. The company is assessing the combination for a potential Phase 1B study to support a potential Phase 2A program in one or more of the following indications:

  • Major Depressive Disorder
  • Neuropathic Pain
  • Levodopa-induced dyskinesia associated with Parkinson’s disease therapy
  • Epilepsy
  • Suicidal Ideation

CNS Therapeutics Market Outlook

The global CNS therapeutics market is estimated to reach $130 billion by 2025. The market was valued at approximately $82.3 billion in 2017 and is anticipated to grow at a healthy CAGR of more than 5.93% from 2018 to 2025. Even before the onset of the anxiety- and depression-provoking stressors from the COVID-19 pandemic, this growth was expected to be driven by a rise in mental illnesses and increased awareness of psychiatric disorders (https://nnw.fm/K2m0s) – all likely to be amplified by the diverse impacts of the pandemic.

The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year. The impact of these conditions is particularly devastating among the young. Industry data suggest that approximately 20% of the world’s children and teens are affected by mental health conditions, and suicide is the leading cause of death among 15- to 29-year-olds (https://nnw.fm/oftNb).

VistaGen’s mission is to help address the unmet needs of patients suffering from CNS disorders whose current treatments are either inadequate or generate debilitating side effects and serious safety concerns, including risk of abuse and death.

“Now more than ever, the new generation anti-anxiety and antidepressant medications we are developing at VistaGen – PH94B, PH10 and AV-101 – are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients whose lives are disrupted by anxiety and depression disorders,” VistaGen CEO and Director Shawn K. Singh said in his closing remarks at the company’s 2020 Annual Meeting of stockholders.

Management Team

Shawn K. Singh, J.D. is the Chief Executive Officer and a Director of VistaGen. He has served on the company’s board of directors since 2000. He has nearly 30 years of experience serving in numerous senior management roles across multiple industries, including private and public biotechnology, pharmaceuticals, medical devices, venture capital, contract research and development, and law. Singh has a B.A. with honors from the University of California – Berkley. He has a J.D. degree from the University of Maryland Carey School of Law. He is also a member of the State Bar of California.

H. Ralph Snodgrass, Ph.D., is the Founder, Chief Scientific Officer and Director of the company. Snodgrass has more than 20 years of experience in the biotechnology field as a senior manager. He is recognized as an expert in stem cell biology, with over 28 years of experience using stem cells as biological research tools to promote development and drug discovery. He received a Ph.D. in immunology from the University of Pennsylvania. Snodgrass has published over 50 scientific papers with more than 17 patents and a number of patent applications.

Mark A. Smith, M.D., Ph.D., is VistaGen’s Chief Medical Officer He has over 20 years of pharmaceutical industry experience, primarily with CNS drug development. Smith has been a successful leader in the discovery and development of approximately 20 investigational new drugs. He has been a part of numerous CNS-related clinical trials. Smith received a bachelor’s and Master of Science from Yale University and a Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California – San Diego. He completed his residency in the psychiatry department at Duke University Medical Center.

Jerrold D. Dotson, CPA, is the Vice President, Chief Financial Officer and Secretary of VistaGen. He has over 25 years of experience in senior management positions in finance and administration at both public and private companies. Dotson is a licensed CPA in California and received his B.S. degree (Cum Laude) in business administration with a concentration in accounting from Abilene Christian College.

Mark A. McPartland is the company’s Vice President of Corporate Development and Investor Relations. He has over 20 years of experience in senior management roles in corporate development and investor relations at both public and private companies. McPartland received his Bachelor’s in business administration and marketing from Coastal Carolina University.

VistaGen Therapeutics Inc. (NASDAQ: VTGN), closed Monday’s trading session at $1.31, off by 5.7554%, on 4,526,903 volume. The average volume for the last 3 months is 1,446,679 and the stock's 52-week low/high is $0.300000011/$1.54999995.

Recent News

Pure Extracts Technologies Corp. (CSE: PULL)

The QualityStocks Daily Newsletter would like to spotlight Pure Extracts Technologies Corp. (CSE: PULL).

Pure Extracts Technologies Inc. (CSE: PULL) was featured today in a publication from PsychedelicNewsWire, examining how psychedelic drugs such as LSD and psilocybin mushrooms are known to cause various effects on different people; those effects range from encounters with entities from out of this world to complete dissolution from the ego. The unique nature of these experiences makes it rather hard for researchers to make definite conclusions concerning the end results of indulging in these psychedelic substances. Also today, the company was featured in the 420 with CNW by CannabisNewsWire.

Pure Extracts Technologies Corp. (CSE: PULL), headquartered in Pemberton, British Columbia, is a plant-based extraction company with a new vertical in functional mushrooms. The firm is positioned to be the dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products.

The Company’s business model consists of three verticals: in-house brands; toll processing, offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to sell under their own brands; and white labelling, supplying products, including edibles and custom formulated oils, in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners.

Market Position

The psychedelic and functional mushroom industries are among the fastest growing in North America. As the industry transitions from dry biomass to extracts, many companies are unprepared for this new opportunity. The global medicinal mushroom market is expected to grow by $13.88 billion annually by 2024.

When assessing investment strategy, market analysts suggest that psychedelics are more comparable to biotech than to cannabis. Unlike traditional biotech, however, psychedelics can claim years of human consumption. Because their efficacy and safety are already well understood, the hurdles for development are likely to be lower. As known molecules, psychedelics won’t spend as much time in discovery and pre-clinical development.

Current research is finding psychedelic benefits including anti-tumor, anti-viral, detoxification, immune function, and mental wellness. As such, psychedelic compounds are now being examined by leading medical research and academic institutions for treatment of depression, PTSD, anxiety, bi-polar disorder, obesity, narcolepsy, OCD, Alzheimer’s, ADHD and drug and alcohol dependence. In 2020, the FDA granted breakthrough therapy status to psychedelics for treatment-resistant depression, with approvals anticipated in 2021.

Pure Extracts is well positioned to partner with organizations planning to develop both functional and psychedelic products. A dealer’s license with Health Canada will enable buying, selling and producing of psychedelics in an EU-GMP-compliant environment. The Company’s 10,000 square foot facility is designed for EU-GMP certification, which allows for international sales. The Company has signed NDAs to explore joint development endeavors for Q4 2020 product launches, as well as an advisory agreement with Dr. Alexander MacGregor, founder of Transpharm Canada Inc. (“TCI”), the parent company of Toronto Institute of Pharmaceutical Technology, whose facility is a fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility and is a full-service clinical development business that provides clinical trial services to biotechnology companies.

Research on Psychedelics

Naturally occurring psychedelics, like psilocybin mushrooms, peyote and ayahuasca, have been used by humans for centuries. First seen as potentially medicinal in 1938 by a chemist at Sandoz Pharmaceuticals (now Novartis), the desired stimulant effect was unsuccessful and therefore the drug was shelved. Twenty years later, in 1958, Sandoz began selling lysergic acid diethylamide (LSD) to treat mental disorders. From 1950 to 1965, over a thousand scientific papers on these compounds were published. During the 1960s, however, psychedelics made their way out of the lab and onto the street. The war on drugs followed, and psychedelic research essentially ended.

Research continued slowly on the fringes. The Multidisciplinary Association for Psychedelic Studies was formed in 1986 with the goal of becoming a leading non-profit psychedelic pharmaceutical company. Still being researched, psychedelics’ primary and most common mechanism of action is agonism of serotonin receptors in the brain, which promotes serotonin production in order to regulate mood.

Growing societal awareness and acceptance of mental illness as a legitimate disease due, in part, to its increasingly prevalence have been a catalyst for a new search for innovative treatments. As such, interest in psychedelic medicines has been revived in recent years.

Extract Segment Leader with Cannabis

Canada’s cannabis industry is dominated by dried flower products. Extract products are estimated to represent only 13% of the market share. With no dominant brands in the cannabis sector, Pure Extracts is the development leader in this segment, which is estimated by Deloitte to be worth $2.7 billion annually. Pure Pulls, the company’s private label brand, is nationally recognized through compliant event sponsorship and ongoing product engagement.

Management Team

Pure Extracts is led by a team of dedicated professionals leveraging extensive industry knowledge.

Ben Nikolaevsky, the company’s CEO, has more than a decade of experience in corporate leadership roles across the natural products, agriculture and cannabis sectors. Nikolaevsky has served as CEO at Natura Naturals Inc. and Blue Goose Capital Corp., as well as market vice president at CIBC and chief credit officer & capital markets manager at IBM Global Financing Canada.

Doug Benville founded Pure Extracts and serves as the company’s COO. He is highly proficient in cannabis cultivation, system operations and oil extraction.

Alexander Logie, Pure Extracts’ vice president of business development, has over 30 years of experience in the financial services sector, having most recently served as interim CFO, COO and senior vice president of business development at Natura Naturals Inc., a licensed cannabis producer acquired at the start of 2019.

Andy Gauvin is vice president of sales for Pure Extracts. Gauvin is an accomplished senior sales leader with over 30 years of experience in the cannabis space. Gauvin also brings extensive knowledge of the complex federal and provincial regulatory environment to the Pure Extracts team.

Pure Extracts Technologies Corp. (CSE: PULL), closed Monday’s trading session at $0.60, off by 3.23%. The average volume for the last 3 months is 402,584 and the stock's 52-week low/high is $0.59/$0.63.

Recent News

InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: IGSTF)

The QualityStocks Daily Newsletter would like to spotlight InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: IGSTF).

InsuraGuest Technologies (TSXV: ISGI), via its wholly-owned subsidiary InsuraGuest Inc., recently signed an Agent Producer Agreement with USI Insurance Services (“USI”), a leading U.S.-based insurance brokerage and consulting firm. Under the agreement, USI will distribute InsuraGuest’s innovative Hospitality Liability coverages through its nationwide network of more than 7,500 professional brokers. To view the full article, visit https://ibn.fm/LVOW7

InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: IGSTF) is a leading global SaaS (Software-as-a-Service) company leveraging its proprietary, flagship insurtech (insurance + technology) software, InsuraGuest, which is integrated with the property management systems of hotels and vacation rentals to deliver custom Hospitality Liability coverages.

InsuraGuest’s Hospitality Liability coverages are purchased by hotels and vacation rental properties, which can address claims from guests and their room occupants. The combination of the integrated software and customized insurance provides the property liability coverages the guests benefit from in the event a loss is incurred during their stay.

The Hospitality Liability policy is offered through integration of InsuraGuest’s API with the clients’ property management systems. InsuraGuest’s platform is currently capable of integrating with approximately 71 different hotel and vacation rental property management systems, giving it access to millions of rooms worldwide.

InsuraGuest continues to pursue expansion opportunities in the United States, and has plans to expand to its distribution platform and Hospitality Liability coverages to the United Kingdom and Europe regions by third quarter 2020, as well as expansion into Asia by the end of 2020.

Protection that Enhances the Guest’s Experience

InsuraGuest’s Hospitality Liability coverages add a layer of protection for the property on a primary basis, should a guest experience an accident or theft while staying at an InsuraGuest member hotel or vacation rental property.

Market Opportunity

The U.S. hotel industry generated more than $218 billion in annual revenues in 2018, an increase of $10 billion from the previous year, according to STR’s 2019 HOST Almanac. The European market is more than double the size of the U.S. market. According to Oxford Economics, there were 6.4 billion nights stayed in the world, with 2.6 billion hotel nights stayed in Asia, 2.8 billion nights stayed in Europe, and 1.1 billion stayed nights in the United States. Additionally, $100 billion was spent on vacation rentals in the United States, where there approximately 4.5 million second homes are being managed by a third-party rental company.

With distribution in Europe and the United States, InsuraGuest’s combined demographics will total 3.9 billion nights stayed, and will more than double its vacation rental opportunities.

Within this burgeoning, high-demand industry is risk of liability to guest injury. For example, gym injuries are among the top five most common hotel accidents. Without proper hedges in place, the property may be liable in a personal injury claim or lawsuit that are not the properties fault.

Though the potential for accidents, slip and falls and mishaps can be widespread, it can be covered under the InsuraGuest Hospitality Liability policy to provide guests a worry-free and enjoyable stay that potentially increases loyalty for the property.

Investment Consideration

  • Targeting hotels and vacation rentals, a multi-billion-dollar industry
  • Providing the first line of defense in case of accident, loss or death
  • Expanding distribution reach with footing in European hotel and vacation rental markets
  • Expansion into Asia by 2020

Executive Team

Douglas Anderson, Chairman & Chief Executive Officer
Douglas Anderson has been a businessman in the real estate industry for nearly 30 years. His business expertise includes master planning and development implementation for larger-scale resorts, business parks and commercial developments across the USA and two provinces in Canada. His business endeavors include the founding of the 7th larger private equity fund in America focusing on multifamily and senior care (ROC Fund/Bridge IPG Fund). He serves as chairman/founder of a golf and winter sports ski holding company with operations in four major east coast markets and British Columbia, Canada.

Anderson earned a Bachelor of Science in consumer studies with an emphasis in architecture as an undergraduate at the University of Utah. He subsequently earned his MBA. He also attended a three-year OPM Program a postgraduate business education at Harvard Business School in Boston. Anderson is an avid skier and outdoor enthusiast.

Logan Anderson, CFO & Director
Logan Anderson (bachelor’s degree in communications, accounting and economics) holds the designation of ACA with the Chartered Accountants of Australia and New Zealand. He began his career as an associate chartered accountant in New Zealand and then Canada. This was followed by his position as controller of a management services company which was responsible for the management of numerous private and publicly traded companies. Since 1993, Anderson has served as president of Amteck Financial Corp. (and its predecessors), a private financial consulting services company servicing both private and public companies. He is a former director of 3D Systems, Inc. (NYSE: DDD), and was formerly a founder, officer, and director of Worldbid.com. Anderson has also been involved in raising funds for numerous private and public companies in all stages of their development and has been an officer and director for numerous public and private companies over the past 40 years.

Charles James Cayias, President & Director
Charles James Cayias is also the president and owner of Charles James Cayias Insurance Inc. He is a third-generation insurance professional whose creativity and artistic vision have enabled him to establish a full-service agency combined with the personal service each client deserves. His outstanding people skills, honesty, integrity and fairness are evident by his loyal and growing clientele, the majority of which are referrals who become long-time customers and friends. Cayias began his insurance career in the early 1970s and has been licensed since 1977. He is licensed in all 50 states and specializes in niche programs. He has extensive expertise in all aspects of the insurance industry including commercial insurance, employee benefits, workers’ compensation, professional liability, risk management and bonding.

Tony Sansone, COO & VP of Finance
Tony Sansone has over 30 years of financial, operations and business development experience which includes serving as CFO in the health care, foodservice distribution, manufacturing and technology sectors, including public company experience. He has held senior finance positions in the banking, telecommunications, medical products, and food & drug retailer industries, closing over $430 million of private debt, equity and line of credit financings and over $350 million of a merger, acquisitions, real estate and state incentive transactions, including due diligence, negotiations, closing, and integration. Sansone coordinated and was the executive sponsor for four ERP implementations and multiple other best-in-class software & technology solutions. He received his MBA from the University of Utah and a Bachelor of Science in accounting from Utah State University. Sansone also currently serves as president-elect of the Utah Chapter of Financial Executives International and a past president and current member of the board of trustees for Catholic Community Services of Utah. He is the proud father of three children.

Christopher J. Panos, Vice President & Director
Christopher J. Panos is a highly competitive sales professional with over 15 years of territory manager sales experience and an award-winning record of achievements. He is exceptionally well organized with a proven work history that demonstrates self-discipline, superb communication skills, and the initiative to achieve both personal and corporate goals. Panos is successful in building relationships with a large network of industry professionals in order to grow and maintain new and existing business, exceed new sales objectives and provide in-depth product training to authorized dealers and sales personnel.

Alexander Walker III ESQ, Corporate Counsel & Director
Alexander Walker III ESQ has served as director of the company since September of 2018 and as counsel to the company since July of 2018. Walker is an attorney and has been a member of the Utah Bar Association since 1987 and a member of the Nevada State Bar since 2003. His practice has involved general business litigation, in both federal and state courts, and transactional work, including securities offerings and registration, corporate formation and periodic reporting compliance. Walker has provided legal services to emerging businesses throughout his carrier and at times has served as an officer and board member as well as legal counsel public companies. His duties as legal counsel for a public company engaged in the business of ownership and operation of coal-producing properties in the western United States included oversight of corporate-related legal matters including securities reporting, corporate compliance, federal and state mining regulation, and employment law oversight. He also has served as the chair of the Mining Committee of the Energy, Natural Resources and Environmental Law Section of the Utah State Bar, a member of the board of directors of the South East Utah Energy Producers Association, the co-chair of the board of the Western Energy Training Center, a board member of the Utah Supreme Court Committee to Review the ABA Recommendations Regarding the Office of Professional Conduct, and a board member of the University of Utah Crimson Club.

Jennifer Epperson, Vice President of Sales
Jennifer Epperson has over 20 years of B2B sales experience with exceptional success history. She has grown and developed sales territories across multiple industries. Her ability to find and develop strategic relationships has given her top-level performance throughout her career. Epperson’s passion and knowledge provide an inherent ability to connect and retain relationships for the growth of the company. Throughout her professional career, she has achieved peak performance sales results and awards year after year. She captures the vision of the company and drives it forward with enthusiasm and expertise. Her commitment to providing an exceptional customer experience has been the key to her success.

Richard Matthews, Interim Financial Controller
Richard Matthews joined the InsuraGuest team in March 2019 as the interim financial controller. Leading the Finance and Audit team, Matthews is responsible for the delivery of financial services such as accounting, treasury, reporting, budgeting and insurance management, in accordance with legislative requirements and organizational policies and strategies. He has over 30 years of experience in providing professional services across a broad range of finance areas including compliance, business process, audit, and financial reporting. He holds a degree in accounting from the University of Utah and is a licensed CPA in the state of Utah.

Roger Bloss, Corporate Consultant & Board Advisor
Roger Bloss joined InsuraGuest in August of 2019 to advise the company and its board on hotel transactions, contributing his knowledge from more than 40 years in the hospitality industry. Bloss previously served in executive positions with several major hotel franchise companies and in 1996 founded Vantage Hospitality Group hotel brands. Under his leadership, Vantage became a Top 10 global hotel company and made the Inc. 500/5000 list of Americas’ fastest-growing private companies for eight straight years. Bloss was named Lodging Magazine’s “Innovator of the Year” in 2006 and 2010, and in 2009 earned a spot on HSMAI’s “Top 25 Extraordinary Minds in Sales and Marketing.” Bloss joined Red Lion Hotels Corporation (RLHC) in September 2016 in conjunction with the acquisition of Vantage.

Jim Kilduff, Board Advisor
James “Jim” C. Kilduff has nearly 40 years of experience in the insurance and risk management sectors. He is a dynamic and energetic team leader and builder with extensive experience in the changes affecting the insurance business through Gas, alternative distribution, insurtechs and program business. His skillset includes experience as chief insurance officer with Outdoorsy Insurance Group, CEO with Harbor Hill Solutions Inc., and senior vice president and chief marketing officer with State National Insurance Companies. His career has spanned MGA creation and management, insurance company management, business development and underwriting, primary insurance and reinsurance.

Don Archibald, Board Advisor
Don Archibald brings to InsuraGuest’s advisory board 54 years of experience as an insurance agent. Archibald is the founder and former owner of Archibald Clarke and Defieux (ACD Insurance), as well as the co-founder and former equity partner of Sussex Insurance, and an agent with Sussex since 2014.

InsuraGuest Technologies, Inc. (TSX.V: ISGI), closed Monday’s trading session at $0.22, off by 4.35%, on 29,460 volume. The average volume for the last 3 months is 99,024 and the stock's 52-week low/high is $0.045/$0.34.

Recent News

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

In a recent “Rolling Stone” article titled “14 Reasons the Entertainment Industry Will Look Different in 2021,” the popular magazine outlines major trends that will shape the entertainment industry in 2021. Given that industry outlook, Friendable (OTC: FDBL) and its innovative Fan Pass platform seem ideally positioned to benefit.

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

  • Live performances or online concerts
  • Backstage meetups before, during or after events
  • Livestreams of studio sessions
  • Behind-the-scenes footage of music video and photo shoots
  • Special interviews and one-on-one videos
  • Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from Livestream.com. The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., Nettaxi.com and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Monday’s trading session at $0.035, off by 12.8269%, on 6,900,710 volume. The average volume for the last 3 months is 1,418,539 and the stock's 52-week low/high is $0.007799999/$0.50.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.